世界の血糖降下薬市場予測 2020年-2025年

【英語タイトル】Global Hypoglycemic Drugs Market Growth 2020-2025

LP Informationが出版した調査資料(LPI20OC2008)・商品コード:LPI20OC2008
・発行会社(調査会社):LP Information
・発行日:2020年10月2日(※2024年版があります。お問い合わせください)
・ページ数:160
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野:Pharma & Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD3,660 ⇒換算¥541,680見積依頼/購入/質問フォーム
Multi User(20名様閲覧用)USD5,490 ⇒換算¥812,520見積依頼/購入/質問フォーム
Corporate User(閲覧人数制限なし)USD7,320 ⇒換算¥1,083,360見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
「血糖降下薬の世界市場」は、地域的には米州、アジア、欧州、中東・アフリカ市場をカバーしており、種類別には、インスリン、DPP-4、GLP-1、SGLT-2、その他など、用途別には、1型糖尿病、2型糖尿病などに区分してまとめた調査レポートです。血糖降下薬のグローバル市場規模、主要地域・主要国別、種類別、用途別の市場予測、主要企業の概要・市場シェア・販売量、市場動向などの情報が含まれています。
・血糖降下薬の世界市場概要(サマリー)
・血糖降下薬の企業別販売量・売上
・血糖降下薬の企業別市場シェア
・血糖降下薬の世界市場規模 2015年-2020年:種類別(インスリン、DPP-4、GLP-1、SGLT-2、その他)
・血糖降下薬の世界市場規模 2015年-2020年:用途別(1型糖尿病、2型糖尿病)
・血糖降下薬の米州市場規模(アメリカ、カナダ、メキシコなど)
・血糖降下薬のアジア市場規模(日本、中国、韓国、インド、東南アジアなど)
・血糖降下薬の欧州市場規模(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・血糖降下薬の中東・アフリカ市場(エジプト、南アフリカ、トルコ、GCC諸国など)
・血糖降下薬市場の成長要因・課題・動向
・血糖降下薬の世界市場予測 2021年-2025年
・血糖降下薬の米州市場予測(アメリカ、カナダ、メキシコなど)
・血糖降下薬のアジア市場予測(日本、中国、韓国、インド、東南アジアなど)
・血糖降下薬の欧州市場予測(ドイツ、フランス、イギリス、イタリア、ロシアなど)
・血糖降下薬の中東・アフリカ市場予測(エジプト、南アフリカ、トルコ、GCC諸国など)
・血糖降下薬の世界市場予測:種類別(インスリン、DPP-4、GLP-1、SGLT-2、その他)
・血糖降下薬の世界市場予測:用途別(1型糖尿病、2型糖尿病)
・主要企業分析
【レポートの概要】

According to this study, over the next five years the Hypoglycemic Drugs market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Hypoglycemic Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Hypoglycemic Drugs market by product type, application, key manufacturers and key regions and countries.

This study specially analyses the impact of Covid-19 outbreak on the Hypoglycemic Drugs, covering the supply chain analysis, impact assessment to the Hypoglycemic Drugs market size growth rate in several scenarios, and the measures to be undertaken by Hypoglycemic Drugs companies in response to the COVID-19 epidemic.

Segmentation by type: breakdown data from 2015 to 2020, in Section 2.3; and forecast to 2025 in section 11.7.
Insulin
DPP-4
GLP-1
SGLT-2
Other

Segmentation by application: breakdown data from 2015 to 2020, in Section 2.4; and forecast to 2024 in section 11.8.
Type 1 Diabetes
Type 2 Diabetes

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Sanofi
Bayer
Merck & Co.
Eli Lilly
Boehringer Ingelheim
Novo Nordisk
AstraZeneca
Novartis
Takeda
Johnson & Johnson
Tonghua DongBao
Hua Dong

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Hypoglycemic Drugs consumption (value & volume) by key regions/countries, type and application, history data from 2015 to 2019, and forecast to 2025.
To understand the structure of Hypoglycemic Drugs market by identifying its various subsegments.
Focuses on the key global Hypoglycemic Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Hypoglycemic Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Hypoglycemic Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

【レポートの目次】

1 Scope of the Report
1.1 Market Introduction
1.2 Research Objectives
1.3 Years Considered
1.4 Market Research Methodology
1.5 Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Hypoglycemic Drugs Consumption 2015-2025
2.1.2 Hypoglycemic Drugs Consumption CAGR by Region
2.2 Hypoglycemic Drugs Segment by Type
2.2.1 Insulin
2.2.2 DPP-4
2.2.3 GLP-1
2.2.4 SGLT-2
2.2.5 Other
2.3 Hypoglycemic Drugs Consumption by Type
2.3.1 Global Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
2.3.2 Global Hypoglycemic Drugs Revenue and Market Share by Type (2015-2020)
2.3.3 Global Hypoglycemic Drugs Sale Price by Type (2015-2020)
2.4 Hypoglycemic Drugs Segment by Application
2.4.1 Type 1 Diabetes
2.4.2 Type 2 Diabetes
2.5 Hypoglycemic Drugs Consumption by Application
2.5.1 Global Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
2.5.2 Global Hypoglycemic Drugs Value and Market Share by Type (2015-2020)
2.5.3 Global Hypoglycemic Drugs Sale Price by Type (2015-2020)

3 Global Hypoglycemic Drugs by Company
3.1 Global Hypoglycemic Drugs Sales Market Share by Company
3.1.1 Global Hypoglycemic Drugs Sales by Company (2018-2020)
3.1.2 Global Hypoglycemic Drugs Sales Market Share by Company (2018-2020)
3.2 Global Hypoglycemic Drugs Revenue Market Share by Company
3.2.1 Global Hypoglycemic Drugs Revenue by Company (2018-2020)
3.2.2 Global Hypoglycemic Drugs Revenue Market Share by Company (2018-2020)
3.3 Global Hypoglycemic Drugs Sale Price by Company
3.4 Global Hypoglycemic Drugs Manufacturing Base Distribution, Sales Area, Type by Company
3.4.1 Global Hypoglycemic Drugs Manufacturing Base Distribution and Sales Area by Company
3.4.2 Players Hypoglycemic Drugs Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2018-2020)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Hypoglycemic Drugs by Regions
4.1 Hypoglycemic Drugs by Regions
4.2 Americas Hypoglycemic Drugs Consumption Growth
4.3 APAC Hypoglycemic Drugs Consumption Growth
4.4 Europe Hypoglycemic Drugs Consumption Growth
4.5 Middle East & Africa Hypoglycemic Drugs Consumption Growth

5 Americas
5.1 Americas Hypoglycemic Drugs Consumption by Countries
5.1.1 Americas Hypoglycemic Drugs Consumption by Countries (2015-2020)
5.1.2 Americas Hypoglycemic Drugs Value by Countries (2015-2020)
5.2 Americas Hypoglycemic Drugs Consumption by Type
5.3 Americas Hypoglycemic Drugs Consumption by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
5.8 Key Economic Indicators of Few Americas Countries

6 APAC
6.1 APAC Hypoglycemic Drugs Consumption by Regions
6.1.1 APAC Hypoglycemic Drugs Consumption by Regions (2015-2020)
6.1.2 APAC Hypoglycemic Drugs Value by Regions (2015-2020)
6.2 APAC Hypoglycemic Drugs Consumption by Type
6.3 APAC Hypoglycemic Drugs Consumption by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 Key Economic Indicators of Few APAC Regions

7 Europe
7.1 Europe Hypoglycemic Drugs by Countries
7.1.1 Europe Hypoglycemic Drugs Consumption by Countries (2015-2020)
7.1.2 Europe Hypoglycemic Drugs Value by Countries (2015-2020)
7.2 Europe Hypoglycemic Drugs Consumption by Type
7.3 Europe Hypoglycemic Drugs Consumption by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
7.9 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa
8.1 Middle East & Africa Hypoglycemic Drugs by Countries
8.1.1 Middle East & Africa Hypoglycemic Drugs Consumption by Countries (2015-2020)
8.1.2 Middle East & Africa Hypoglycemic Drugs Value by Countries (2015-2020)
8.2 Middle East & Africa Hypoglycemic Drugs Consumption by Type
8.3 Middle East & Africa Hypoglycemic Drugs Consumption by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Hypoglycemic Drugs Distributors
10.3 Hypoglycemic Drugs Customer

11 Global Hypoglycemic Drugs Market Forecast
11.1 Global Hypoglycemic Drugs Consumption Forecast (2021-2025)
11.2 Global Hypoglycemic Drugs Forecast by Regions
11.2.1 Global Hypoglycemic Drugs Forecast by Regions (2021-2025)
11.2.2 Global Hypoglycemic Drugs Value Forecast by Regions (2021-2025)
11.2.3 Americas Consumption Forecast
11.2.4 APAC Consumption Forecast
11.2.5 Europe Consumption Forecast
11.2.6 Middle East & Africa Consumption Forecast
11.3 Americas Forecast by Countries
11.3.1 United States Market Forecast
11.3.2 Canada Market Forecast
11.3.3 Mexico Market Forecast
11.3.4 Brazil Market Forecast
11.4 APAC Forecast by Countries
11.4.1 China Market Forecast
11.4.2 Japan Market Forecast
11.4.3 Korea Market Forecast
11.4.4 Southeast Asia Market Forecast
11.4.5 India Market Forecast
11.4.6 Australia Market Forecast
11.5 Europe Forecast by Countries
11.5.1 Germany Market Forecast
11.5.2 France Market Forecast
11.5.3 UK Market Forecast
11.5.4 Italy Market Forecast
11.5.5 Russia Market Forecast
11.6 Middle East & Africa Forecast by Countries
11.6.1 Egypt Market Forecast
11.6.2 South Africa Market Forecast
11.6.3 Israel Market Forecast
11.6.4 Turkey Market Forecast
11.6.5 GCC Countries Market Forecast
11.7 Global Hypoglycemic Drugs Forecast by Type
11.8 Global Hypoglycemic Drugs Forecast by Application

12 Key Players Analysis
12.1 Sanofi
12.1.1 Company Information
12.1.2 Hypoglycemic Drugs Product Offered
12.1.3 Sanofi Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.1.4 Main Business Overview
12.1.5 Sanofi Latest Developments
12.2 Bayer
12.2.1 Company Information
12.2.2 Hypoglycemic Drugs Product Offered
12.2.3 Bayer Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.2.4 Main Business Overview
12.2.5 Bayer Latest Developments
12.3 Merck & Co.
12.3.1 Company Information
12.3.2 Hypoglycemic Drugs Product Offered
12.3.3 Merck & Co. Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.3.4 Main Business Overview
12.3.5 Merck & Co. Latest Developments
12.4 Eli Lilly
12.4.1 Company Information
12.4.2 Hypoglycemic Drugs Product Offered
12.4.3 Eli Lilly Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.4.4 Main Business Overview
12.4.5 Eli Lilly Latest Developments
12.5 Boehringer Ingelheim
12.5.1 Company Information
12.5.2 Hypoglycemic Drugs Product Offered
12.5.3 Boehringer Ingelheim Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.5.4 Main Business Overview
12.5.5 Boehringer Ingelheim Latest Developments
12.6 Novo Nordisk
12.6.1 Company Information
12.6.2 Hypoglycemic Drugs Product Offered
12.6.3 Novo Nordisk Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.6.4 Main Business Overview
12.6.5 Novo Nordisk Latest Developments
12.7 AstraZeneca
12.7.1 Company Information
12.7.2 Hypoglycemic Drugs Product Offered
12.7.3 AstraZeneca Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.7.4 Main Business Overview
12.7.5 AstraZeneca Latest Developments
12.8 Novartis
12.8.1 Company Information
12.8.2 Hypoglycemic Drugs Product Offered
12.8.3 Novartis Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.8.4 Main Business Overview
12.8.5 Novartis Latest Developments
12.9 Takeda
12.9.1 Company Information
12.9.2 Hypoglycemic Drugs Product Offered
12.9.3 Takeda Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.9.4 Main Business Overview
12.9.5 Takeda Latest Developments
12.10 Johnson & Johnson
12.10.1 Company Information
12.10.2 Hypoglycemic Drugs Product Offered
12.10.3 Johnson & Johnson Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.10.4 Main Business Overview
12.10.5 Johnson & Johnson Latest Developments
12.11 Tonghua DongBao
12.11.1 Company Information
12.11.2 Hypoglycemic Drugs Product Offered
12.11.3 Tonghua DongBao Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.11.4 Main Business Overview
12.11.5 Tonghua DongBao Latest Developments
12.12 Hua Dong
12.12.1 Company Information
12.12.2 Hypoglycemic Drugs Product Offered
12.12.3 Hua Dong Hypoglycemic Drugs Sales, Revenue, Price and Gross Margin (2018-2020)
12.12.4 Main Business Overview
12.12.5 Hua Dong Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Research Methodology
Table 2. Data Source
Table 3. Hypoglycemic Drugs Consumption CAGR by Region 2015-2025 ($ Millions)
Table 4. Major Players of Insulin
Table 5. Major Players of DPP-4
Table 6. Major Players of GLP-1
Table 7. Major Players of SGLT-2
Table 8. Major Players of Other
Table 9. Global Consumption Sales by Type (2015-2020)
Table 10. Global Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 11. Global Hypoglycemic Drugs Revenue by Type (2015-2020) ($ million)
Table 12. Global Hypoglycemic Drugs Value Market Share by Type (2015-2020) ($ Millions)
Table 13. Global Hypoglycemic Drugs Sale Price by Type (2015-2020)
Table 14. Global Consumption Sales by Application (2015-2020)
Table 15. Global Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 16. Global Hypoglycemic Drugs Value by Application (2015-2020)
Table 17. Global Hypoglycemic Drugs Value Market Share by Application (2015-2020)
Table 18. Global Hypoglycemic Drugs Sale Price by Application (2015-2020)
Table 19. Global Hypoglycemic Drugs Sales by Company (2017-2019) (K Units)
Table 20. Global Hypoglycemic Drugs Sales Market Share by Company (2017-2019)
Table 21. Global Hypoglycemic Drugs Revenue by Company (2017-2019) ($ Millions)
Table 22. Global Hypoglycemic Drugs Revenue Market Share by Company (2017-2019)
Table 23. Global Hypoglycemic Drugs Sale Price by Company (2017-2019)
Table 24. Global Hypoglycemic Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
Table 25. Players Hypoglycemic Drugs Products Offered
Table 26. Hypoglycemic Drugs Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
Table 27. Global Hypoglycemic Drugs Consumption by Regions 2015-2020 (K Units)
Table 28. Global Hypoglycemic Drugs Consumption Market Share by Regions 2015-2020
Table 29. Global Hypoglycemic Drugs Value by Regions 2015-2020 ($ Millions)
Table 30. Global Hypoglycemic Drugs Value Market Share by Regions 2015-2020
Table 31. Americas Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 32. Americas Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 33. Americas Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 34. Americas Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 35. Americas Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 36. Americas Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 37. Americas Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 38. Americas Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 39. APAC Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 40. APAC Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 41. APAC Hypoglycemic Drugs Value by Regions (2015-2020) ($ Millions)
Table 42. APAC Hypoglycemic Drugs Value Market Share by Regions (2015-2020)
Table 43. APAC Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 44. APAC Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 45. APAC Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 46. APAC Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 47. Europe Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 48. Europe Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 49. Europe Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 50. Europe Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 51. Europe Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 52. Europe Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 53. Europe Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 54. Europe Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 55. Middle East & Africa Hypoglycemic Drugs Consumption by Countries (2015-2020) (K Units)
Table 56. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Countries (2015-2020)
Table 57. Middle East & Africa Hypoglycemic Drugs Value by Countries (2015-2020) ($ Millions)
Table 58. Middle East & Africa Hypoglycemic Drugs Value Market Share by Countries (2015-2020)
Table 59. Middle East & Africa Hypoglycemic Drugs Consumption by Type (2015-2020) (K Units)
Table 60. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Table 61. Middle East & Africa Hypoglycemic Drugs Consumption by Application (2015-2020) (K Units)
Table 62. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Table 63. Hypoglycemic Drugs Distributors List
Table 64. Hypoglycemic Drugs Customer List
Table 65. Global Hypoglycemic Drugs Consumption Forecast by Countries (2021-2025) (K Units)
Table 66. Global Hypoglycemic Drugs Consumption Market Forecast by Regions
Table 67. Global Hypoglycemic Drugs Value Forecast by Countries (2021-2025) ($ Millions)
Table 68. Global Hypoglycemic Drugs Value Market Share Forecast by Regions
Table 69. Global Hypoglycemic Drugs Consumption Forecast by Type (2021-2025) (K Units)
Table 70. Global Hypoglycemic Drugs Consumption Market Share Forecast by Type (2021-2025)
Table 71. Global Hypoglycemic Drugs Value Forecast by Type (2021-2025) ($ Millions)
Table 72. Global Hypoglycemic Drugs Value Market Share Forecast by Type (2021-2025)
Table 73. Global Hypoglycemic Drugs Consumption Forecast by Application (2021-2025) (K Units)
Table 74. Global Hypoglycemic Drugs Consumption Market Share Forecast by Application (2021-2025)
Table 75. Global Hypoglycemic Drugs Value Forecast by Application (2021-2025) ($ Millions)
Table 76. Global Hypoglycemic Drugs Value Market Share Forecast by Application (2021-2025)
Table 77. Sanofi Product Offered
Table 78. Sanofi Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 79. Sanofi Main Business
Table 80. Sanofi Latest Developments
Table 81. Sanofi Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 82. Bayer Product Offered
Table 83. Bayer Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 84. Bayer Main Business
Table 85. Bayer Latest Developments
Table 86. Bayer Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 87. Merck & Co. Product Offered
Table 88. Merck & Co. Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 89. Merck & Co. Main Business
Table 90. Merck & Co. Latest Developments
Table 91. Merck & Co. Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 92. Eli Lilly Product Offered
Table 93. Eli Lilly Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 94. Eli Lilly Main Business
Table 95. Eli Lilly Latest Developments
Table 96. Eli Lilly Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 97. Boehringer Ingelheim Product Offered
Table 98. Boehringer Ingelheim Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 99. Boehringer Ingelheim Main Business
Table 100. Boehringer Ingelheim Latest Developments
Table 101. Boehringer Ingelheim Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 102. Novo Nordisk Product Offered
Table 103. Novo Nordisk Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 104. Novo Nordisk Main Business
Table 105. Novo Nordisk Latest Developments
Table 106. Novo Nordisk Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 107. AstraZeneca Product Offered
Table 108. AstraZeneca Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 109. AstraZeneca Main Business
Table 110. AstraZeneca Latest Developments
Table 111. AstraZeneca Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 112. Novartis Product Offered
Table 113. Novartis Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 114. Novartis Main Business
Table 115. Novartis Latest Developments
Table 116. Novartis Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 117. Takeda Product Offered
Table 118. Takeda Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 119. Takeda Main Business
Table 120. Takeda Latest Developments
Table 121. Takeda Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 122. Johnson & Johnson Product Offered
Table 123. Johnson & Johnson Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 124. Johnson & Johnson Main Business
Table 125. Johnson & Johnson Latest Developments
Table 126. Johnson & Johnson Basic Information, Company Total Revenue (in $ million), Hypoglycemic Drugs Manufacturing Base, Sales Area and Its Competitors
Table 127. Tonghua DongBao Product Offered
Table 128. Tonghua DongBao Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 129. Tonghua DongBao Main Business
Table 130. Tonghua DongBao Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 131. Tonghua DongBao Latest Developments
Table 132. Hua Dong Product Offered
Table 133. Hua Dong Hypoglycemic Drugs Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2020E)
Table 134. Hua Dong Main Business
Table 135. Hua Dong Basic Information, Manufacturing Base, Sales Area and Its Competitors
Table 136. Hua Dong Latest Developments
List of Figures
Figure 1. Picture of Hypoglycemic Drugs
Figure 2. Hypoglycemic Drugs Report Years Considered
Figure 3. Market Research Methodology
Figure 4. Global Hypoglycemic Drugs Consumption Growth Rate 2015-2025 (K Units)
Figure 5. Global Hypoglycemic Drugs Value Growth Rate 2015-2025 ($ Millions)
Figure 6. Product Picture of Insulin
Figure 7. Product Picture of DPP-4
Figure 8. Product Picture of GLP-1
Figure 9. Product Picture of SGLT-2
Figure 10. Product Picture of Other
Figure 11. Global Hypoglycemic Drugs Consumption Market Share by Type (2015-2020)
Figure 12. Global Hypoglycemic Drugs Value Market Share by Type (2015-2020)
Figure 13. Hypoglycemic Drugs Consumed in Type 1 Diabetes
Figure 14. Global Hypoglycemic Drugs Market: Type 1 Diabetes (2015-2020) (K Units)
Figure 15. Global Hypoglycemic Drugs Market: Type 1 Diabetes (2015-2020) ($ Millions)
Figure 16. Hypoglycemic Drugs Consumed in Type 2 Diabetes
Figure 17. Global Hypoglycemic Drugs Market: Type 2 Diabetes (2015-2020) (K Units)
Figure 18. Global Hypoglycemic Drugs Market: Type 2 Diabetes (2015-2020) ($ Millions)
Figure 19. Global Hypoglycemic Drugs Consumption Market Share by Application (2015-2020)
Figure 20. Global Hypoglycemic Drugs Value Market Share by Application (2015-2020)
Figure 21. Global Hypoglycemic Drugs Sales Market Share by Company in 2017
Figure 22. Global Hypoglycemic Drugs Sales Market Share by Company in 2019
Figure 23. Global Hypoglycemic Drugs Revenue Market Share by Company in 2017
Figure 24. Global Hypoglycemic Drugs Revenue Market Share by Company in 2019
Figure 25. Global Hypoglycemic Drugs Sale Price by Company in 2019
Figure 26. Global Hypoglycemic Drugs Consumption Market Share by Regions 2015-2020
Figure 27. Global Hypoglycemic Drugs Value Market Share by Regions 2015-2020
Figure 28. Americas Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 29. Americas Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 30. APAC Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 31. APAC Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 32. Europe Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 33. Europe Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 34. Middle East & Africa Hypoglycemic Drugs Consumption 2015-2020 (K Units)
Figure 35. Middle East & Africa Hypoglycemic Drugs Value 2015-2020 ($ Millions)
Figure 36. Americas Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 37. Americas Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 38. Americas Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 39. Americas Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 40. United States Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 41. United States Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 42. Canada Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 43. Canada Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 44. Mexico Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 45. Mexico Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 46. APAC Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 47. APAC Hypoglycemic Drugs Value Market Share by Regions in 2019
Figure 48. APAC Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 49. APAC Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 50. China Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 51. China Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 52. Japan Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 53. Japan Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 54. Korea Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 55. Korea Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 56. Southeast Asia Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 57. Southeast Asia Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 58. India Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 59. India Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 60. Australia Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 61. Australia Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 62. Europe Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 63. Europe Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 64. Europe Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 65. Europe Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 66. Germany Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 67. Germany Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 68. France Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 69. France Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 70. UK Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 71. UK Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 72. Italy Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 73. Italy Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 74. Russia Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 75. Russia Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 76. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Countries in 2019
Figure 77. Middle East & Africa Hypoglycemic Drugs Value Market Share by Countries in 2019
Figure 78. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Type in 2019
Figure 79. Middle East & Africa Hypoglycemic Drugs Consumption Market Share by Application in 2019
Figure 80. Egypt Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 81. Egypt Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 82. South Africa Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 83. South Africa Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 84. Israel Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 85. Israel Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 86. Turkey Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 87. Turkey Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 88. GCC Countries Hypoglycemic Drugs Consumption Growth 2015-2020 (K Units)
Figure 89. GCC Countries Hypoglycemic Drugs Value Growth 2015-2020 ($ Millions)
Figure 90. Global Hypoglycemic Drugs Consumption Growth Rate Forecast (2021-2025) (K Units)
Figure 91. Global Hypoglycemic Drugs Value Growth Rate Forecast (2021-2025) ($ Millions)
Figure 92. Americas Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 93. Americas Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 94. APAC Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 95. APAC Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 96. Europe Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 97. Europe Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 98. Middle East & Africa Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 99. Middle East & Africa Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 100. United States Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 101. United States Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 102. Canada Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 103. Canada Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 104. Mexico Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 105. Mexico Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 106. Brazil Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 107. Brazil Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 108. China Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 109. China Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 110. Japan Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 111. Japan Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 112. Korea Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 113. Korea Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 114. Southeast Asia Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 115. Southeast Asia Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 116. India Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 117. India Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 118. Australia Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 119. Australia Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 120. Germany Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 121. Germany Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 122. France Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 123. France Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 124. UK Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 125. UK Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 126. Italy Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 127. Italy Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 128. Russia Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 129. Russia Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 130. Spain Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 131. Spain Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 132. Egypt Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 133. Egypt Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 134. South Africa Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 135. South Africa Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 136. Israel Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 137. Israel Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 138. Turkey Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 139. Turkey Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 140. GCC Countries Hypoglycemic Drugs Consumption 2021-2025 (K Units)
Figure 141. GCC Countries Hypoglycemic Drugs Value 2021-2025 ($ Millions)
Figure 142. Sanofi Hypoglycemic Drugs Market Share (2018-2020)
Figure 143. Bayer Hypoglycemic Drugs Market Share (2018-2020)
Figure 144. Merck & Co. Hypoglycemic Drugs Market Share (2018-2020)
Figure 145. Eli Lilly Hypoglycemic Drugs Market Share (2018-2020)
Figure 146. Boehringer Ingelheim Hypoglycemic Drugs Market Share (2018-2020)
Figure 147. Novo Nordisk Hypoglycemic Drugs Market Share (2018-2020)
Figure 148. AstraZeneca Hypoglycemic Drugs Market Share (2018-2020)
Figure 149. Novartis Hypoglycemic Drugs Market Share (2018-2020)
Figure 150. Takeda Hypoglycemic Drugs Market Share (2018-2020)
Figure 151. Johnson & Johnson Hypoglycemic Drugs Market Share (2018-2020)
Figure 152. Tonghua DongBao Hypoglycemic Drugs Market Share (2018-2020)
Figure 153. Hua Dong Hypoglycemic Drugs Market Share (2018-2020)


★調査レポート[世界の血糖降下薬市場予測 2020年-2025年] (コード:LPI20OC2008)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の血糖降下薬市場予測 2020年-2025年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆